



## **AgiOS to Webcast Conference Call of Fourth Quarter and Full Year 2018 Financial Results on February 14, 2019**

January 31, 2019

CAMBRIDGE, Mass., Jan. 31, 2019 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today announced that the company will host a conference call and live webcast on Thursday, February 14, 2019 at 8:00 a.m. ET to report its fourth quarter and full year 2018 financial results and other business highlights.

A live webcast can be accessed under "Events & Presentations" in the Investors section of the company's website at [www.agios.com](http://www.agios.com). The conference call can be accessed by dialing 1-877-377-7098 (domestic) or 1-631-291-4547 (international) and referring to conference ID 9886713. The webcast will be archived and made available for replay on the company's website beginning approximately two hours after the event.

### **About Agios**

AgiOS is focused on discovering and developing novel investigational medicines to treat cancer and rare genetic diseases through scientific leadership in the field of cellular metabolism. In addition to an active research and discovery pipeline across both therapeutic areas, Agios has two approved oncology precision medicines and multiple first-in-class investigational therapies in clinical and/or preclinical development. All Agios programs focus on genetically identified patient populations, leveraging our knowledge of metabolism, biology and genomics. For more information, please visit the company's website at [www.agios.com](http://www.agios.com).

### **Contacts**

#### **AgiOS Investors Contact:**

Kendra Adams, 617-844-6407  
Senior Director, Investor & Public Relations  
[Kendra.Adams@agios.com](mailto:Kendra.Adams@agios.com)

#### **AgiOS Media Contact:**

Holly Manning, 617-844-6630  
Associate Director, Corporate Communications  
[Holly.Manning@agios.com](mailto:Holly.Manning@agios.com)



Source: Agios Pharmaceuticals, Inc.